Search
Now showing items 1-8 of 8
Current Advances in CAR T Cell Therapy for Malignant Mesothelioma.
(Scientific Archives LLC, 2020-06-22)
Malignant mesothelioma is a relatively rare malignancy arising in the body's serosal surfaces, with malignant pleural mesothelioma (MPM) being the most common type. It is characterized by local spread within the thorax, ...
Mesothelin-targeted CAR-T cell therapy for solid tumors.
(TAYLOR & FRANCIS LTD, 2021-04-03)
Introduction: Mesothelin (MSLN) is a tumor differentiation antigen normally restricted to the body's mesothelial surfaces, but significantly overexpressed in a broad range of solid tumors. For this reason, MSLN has emerged ...
Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model.
(CELL PRESS, 2020-09-25)
The therapeutic efficacy of adoptive transfer of T cells transduced with chimeric antigen receptors (CARs) has been limited in the treatment of solid cancers, partly due to tumor antigen heterogeneity. Overcoming lack of ...
Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.
(ELSEVIER IRELAND LTD, 2017-05-01)
Malignant mesothelioma remains an incurable cancer. We demonstrated that mesotheliomas expressed EGFR (79.2%), ErbB4 (49.0%) and HER2 (6.3%), but lacked ErbB3. At least one ErbB family member was expressed in 88% of tumors. ...
Armored CAR T-Cells: The Next Chapter in T-Cell Cancer Immunotherapy.
(DOVE MEDICAL PRESS LTD, 2021-01-01)
Chimeric antigen receptor (CAR) T-cell therapy engineers T-cells to express a synthetic receptor which redirects effector function to the tumor, to improve efficacy and reduce toxicities associated with conventional ...
Precision-Cut Tumor Slices (PCTS) as an Ex Vivo Model in Immunotherapy Research.
(MDPI, 2022-04-06)
Precision-cut tumor slices (PCTS) have recently emerged as important ex vivo human tumor models, offering the opportunity to study individual patient responses to targeted immunotherapies, including CAR-T cell therapies. ...
Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).
(MDPI, 2017-09-01)
Cancer immunotherapy has now become a recognized approach to treating cancers. In addition to checkpoint blockade, adoptive T cell transfer (ACT) using chimeric antigen receptors (CARs) has shown impressive clinical outcomes ...
Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy.
(AMER ASSOC CANCER RESEARCH, 2023-09-11)
UNLABELLED: Surgical cytoreduction for patients with malignant pleural mesothelioma (MPM) is used for selected patients as a part of multi-modality management strategy. Our group has previously described the clinical use ...